Bristol-Myers Squibb Announce Positive Q3 Results

Bristol-Myers Squibb have announced positive third quarter results for 2014, beating earlier forecasts after stronger-than-expected revenues for the period. The biopharmaceutical company posted earnings on Friday of $721 million, or $0.43 a share, an increase from earnings of $692 million, or $0.42 per share, in Q3 of 2013.  Once adjusted for special items, Bristol-Myers Squibb’s

Continue Reading

Roche Reports Positive Q3 2014 Results

Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla.  Sales of Perjeta more than tripled to reach

Continue Reading

Merck KGaA Partners with ICR and Wellcome Trust to Develop Anti-Cancer Drugs

Merck KGaA have today announced a new partnership with the Institute of Cancer Research (ICR) and the Wellcome Trust to develop cancer treatments. Merck KGaA’s Merck Serono unit will work with the UK organisations to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase (PARP) enzyme family. Specifically, the Institute of Cancer Research

Continue Reading

Bayer to Increase Pharmaceutical R&D Spend

Bayer have announced additional details on the future of their pharmaceutical research and development business following the announcement earlier this week that they will be concentrating on their healthcare and crop science businesses going forward. The announcement confirmed Bayer plans to float their material science division on the stock market and focus on life sciences,

Continue Reading

Janssen’s Affiliate Cilag to Acquire Covagen

Janssen affiliate’s Cilag GmbH International has announced that they will be acquiring Swiss biotech Covagen AG for an undisclosed sum. The purchase was finalised in a deal brokered by Johnson & Johnson Innovation Center in London. Covagen specialises in the development of multi-specific protein therapeutics through their FynomAb technology platform, which binds proteins to antibodies,

Continue Reading

Cubist Pharmaceuticals Announce New Zurich Office

Cubist Pharmaceuticals, who specialise in the development of antibiotics for infectious diseases, has announced the launch of their new international headquarters based in Zurich, Switzerland. The new office will expand Cubist’s presence outside of the US, allowing the company to reinforce their commitment to the major public health threat of antimicrobial resistance. Patrick Vink, who

Continue Reading